Korglutide

Korglutide
Product Description

Korglutide is a next-generation oral dual GLP-1R/IGF-1R peptide designed to support safe and muscle-preserving weight loss as a non-injectable nutraceutical alternative.
Product Overview
Korglutide is a synthetic dual GLP-1R and IGF-1R agonist peptide developed by Caregen for weight management and metabolic health. Unlike injectable GLP-1 therapies, it is designed for once-daily oral administration, offering a convenient and non-invasive alternative. Korglutide supports fat-selective weight reduction while preserving lean muscle mass and improves glycemic control in individuals with type 2 diabetes. In January 2026, it completed the U.S. FDA New Dietary Ingredient (NDI) notification process.

Read more Show less

Caregen Co.,Ltd.

  • Country/Region:
    Korea, Republic Of
  • Founded:
    2001
  • On CPHI since:
    2016
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
Biopharmaceutical company
Consumer Goods
Distributor/Import Export
Drug delivery device Supplier/Manufacturer
Manufacturer/Innovator
OTC
Other
Primary activities
API Producer
Biopharmaceutical
Cosmeceuticals
Cosmetic Ingredients
Nutraceuticals
OTC
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less
Specifications
  • Details
    Human Clinical Results
    1) Obese & Overweight Individuals (with/without type 2 diabetes)
    - Body weight reduction: -10.78% (-9.3 kg)
    - BMI reduction: -10.83%
    - HbA1c reduction: -10.98%
    - Waist-to-hip ratio (WHR): -5.21%
    - Body fat mass reduction: -20.71% (-7.0 kg)
    - Skeletal muscle mass reduction: limited to -0.75% (-0.27 kg)
    - Muscle ratio increased by +11.40%, indicating fat-selective weight loss with muscle preservation


    2) Non-Obese Individuals (including NWO)
    - Body weight reduction: -8.02% (-5.2 kg)
    - BMI reduction: -8.26%
    - Body fat reduction: -9.6%
    - Visceral fat level reduction: -9.21%
More specifications Fewer specifications

Caregen Co.,Ltd.

  • Country/Region:
    Korea, Republic Of
  • Founded:
    2001
  • On CPHI since:
    2016
  • Certificates:
    3
  • Employees:
    100 - 249
Company types
Biopharmaceutical company
Consumer Goods
Distributor/Import Export
Drug delivery device Supplier/Manufacturer
Manufacturer/Innovator
OTC
Other
Primary activities
API Producer
Biopharmaceutical
Cosmeceuticals
Cosmetic Ingredients
Nutraceuticals
OTC
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile

More Products from Caregen Co.,Ltd. (5)

  • CG-P5

    Product CG-P5

    First-in-Class VEGFR2-Inhibiting Peptide Eye Drop for Wet Age-Related Macular Degeneration

    Product Overview: A New Standard for Non-Invasive Retinal Therapy
    CG-P5 is a first-in-class VEGFR2-inhibiting biomimetic peptide developed as a topical eye drop for the treatment of wet age-related m...
  • CG-T1

    Product CG-T1

    Peptide-Based Topical Therapeutic for Dry Eye Disease (DED)

    Product Overview: A Restorative Approach to Dry Eye Disease

    CG-T1 is a next-generation peptide-based topical therapy for dry eye disease, advancing toward Phase 2 clinical development in the United States following successfu...
  • MyoKi

    Product MyoKi

    MyoKi is an oral anti-myostatin peptide designed to support muscle mass and strength, enabling safe and effective muscle health management across all age groups.

    Product OverviewMyoKi is a peptide-based nutraceutical developed to support muscle preservation and functional performance t...
  • ProGsterol

    Product ProGsterol

    ProGsterol is an oral peptide-based nutraceutical designed to improve insulin receptor sensitivity and regulate glucose metabolism, supporting overall metabolic balance.
    Product Overview
    ProGsterol is a peptide-based nutraceutical developed by Caregen for metabolic disorders, including insulin re...
  • CG-Luxidase

    Product CG-Luxidase

    CG-Luxidase is a proprietary peptide-based delivery platform designed to enhance the penetration and distribution of active compounds by transiently modulating the hyaluronic acid (HA) network within the extracellular matrix (ECM).

    As a water-soluble synthetic decapeptide (INCI: Decapeptide-51),...

Caregen Co.,Ltd. resources (1)